4-(3-amino-benzyl)-2H-phthalazin-1-one | 420846-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(3-amino-benzyl)-2H-phthalazin-1-one
• 英文别名: 4-(3-aminobenzyl)-2H-phthalazin-1-one；4-[(3-aminophenyl)methyl]-2H-phthalazin-1-one
• CAS: 420846-57-7
• 化学式: C₁₅H₁₃N₃O
• 分子量: 251.288
• InChiKey: JSWPSDADCDNXOE-UHFFFAOYSA-N

物化性质

• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-amino-benzyl)-2H-phthalazin-1-one 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 2-[3-(4-oxo-3,4-dihydrophthalazin-1-ylmethyl)phenyl]isoindole-1,3-dione
  参考文献：
  名称：

  Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase

  摘要：

  Screening of the Maybridge compound collection identified 4-arylphthalazinones as micromolar inhibitors of PARP-1 catalytic activity. Subsequent optimisation of both inhibitory activity and metabolic stability led to a novel series of meta-substituted 4-benzyl-2H-phthalazin-1-ones with low nanomolar, cellular activity as PARP-1 inhibitors and promising metabolic stability in vitro. © 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.026
• 作为产物：
  描述：

  2-(3-硝基苯基)茚-1,3-二酮 在 肼 作用下， 反应 2.0h， 生成 4-(3-amino-benzyl)-2H-phthalazin-1-one
  参考文献：
  名称：

  [EN] PHTHALAZINONE DERIVATIVES
  [FR] DERIVES DE PHTHALAZINONE

  摘要：

  一种具有化学式（I）的化合物；或其异构体、盐、溶剂合物、化学保护形式、或前药，其中A和B共同代表一个可选择取代的融合芳香环；RL是一个C5-7芳基基团，在邻位由基团R2取代，并可选择进一步取代；其中R2选自化学式（II）和化学式（III）；以及其作为药物的用途，特别用于治疗通过抑制PARP活性改善的疾病。

  公开号：

  WO2003093261A1

文献信息

• [EN] PHTHALAZINONE DERIVATIVES<br/>[FR] DERIVES DE PHTHALAZINONE
  申请人：KUDOS PHARM LTD

  公开号：WO2003093261A1

  公开（公告）日：2003-11-13

  A compound of formula (I); or an isomer, salt, solvate, chemically protected form, or prodrug thereof, wherein A and B together represent an optionally substituted, fused aromatic ring; RL is a C5-7 aryl group substituted in the meta position by the group R2, and optionally further substituted; wherein R2 is selected from formula (II) and formula (III); and its use as a pharmaceutical, in particular for the treatment of diseases ameliorated by inhibiting the activity of PARP.

  一种具有化学式（I）的化合物；或其异构体、盐、溶剂合物、化学保护形式、或前药，其中A和B共同代表一个可选择取代的融合芳香环；RL是一个C5-7芳基基团，在邻位由基团R2取代，并可选择进一步取代；其中R2选自化学式（II）和化学式（III）；以及其作为药物的用途，特别用于治疗通过抑制PARP活性改善的疾病。
• PHTHALAZINONE DERIVATIVES
  申请人：Javaid Hashim Muhammad

  公开号：US20070093489A1

  公开（公告）日：2007-04-26

  A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; D is selected from: (i) where Y 1 is selected from CH and N, Y 2 is selected from CH and N, Y 3 is selected from CH, CF and N; and (ii) and where Q is O or S; R D is: wherein R N1 is selected from H and optionally substituted C 1-10 alkyl; X is selected from a single bond, NR N2 , CR C3 R C4 and C═O; R N2 is selected from H and optionally substituted C 1-10 alkyl; R C3 and R C4 are independently selected from H, R, C(═O)OR, where R is optionally substituted C 1-10 alkyl, optionally substituted C 5-20 aryl or optionally substituted C 3-20 heterocyclyl; Y is selected from NR N3 and CR C1 R C2 ; R C1 and R C2 are independently selected from H, R, C(═O)OR, where R is optionally substituted C 1-10 alkyl, optionally substituted C 5-20 aryl or optionally substituted C 3-20 heterocyclyl; R C1 and R C2 together with the carbon atom to which they are attached may form an optionally substituted spiro-fused C 5-7 carbocylic or heterocyclic ring; and when X is a single bond R N1 and R C2 may together with the N and C atoms to which they are bound, form an optionally substituted C 5-7 heterocylic ring; and when X is CR C3 R C4 , R C2 and R C4 may together form an additional bond, such that there is a double bond between the atoms substituted by R C1 and R C3 .

  式(I)的化合物：其中：A和B一起代表一个可选择取代的、融合的芳香环；D选择自：(i)其中Y1选择自CH和N，Y2选择自CH和N，Y3选择自CH、CF和N；和(ii)其中Q是O或S；RD是：其中RN1选择自H和可选择取代的C1-10烷基；X选择自单键、NRN2、CRC3RC4和C═O；RN2选择自H和可选择取代的C1-10烷基；RC3和RC4独立选择自H、R、C(═O)OR，其中R是可选择取代的C1-10烷基、可选择取代的C5-20芳基或可选择取代的C3-20杂环烷基；Y选择自NRN3和CRC1RC2；RC1和RC2独立选择自H、R、C(═O)OR，其中R是可选择取代的C1-10烷基、可选择取代的C5-20芳基或可选择取代的C3-20杂环烷基；RC1和RC2与它们连接的碳原子一起可以形成一个可选择取代的螺联的C5-7碳环或杂环；当X是单键时，RN1和RC2可以与它们连接的N和C原子一起形成一个可选择取代的C5-7杂环；当X是CRC3RC4时，RC2和RC4可以一起形成一个额外的键，使得由RC1和RC3取代的原子之间有一个双键。
• Phthalazinone derivatives
  申请人：KuDOS Pharmaceuticals Limited

  公开号：US20040023968A1

  公开（公告）日：2004-02-05

  A compound of formula: 1 or an isomer, salt, solvate, chemically protected form, or prodrug thereof, wherein A and B together represent an optionally substituted, fused aromatic ring; R L is a C 5-7 aryl group substituted in the meta position by the group R 2 , and optionally further substituted; wherein R 2 is selected from: 2 and its use as a pharmaceutical, in particular for the treatment of diseases ameliorated by inhibiting the activity of PARP.

  一种化合物，其分子式为1或其异构体、盐、溶剂合物、化学保护形式或前药，其中A和B在一起代表一个可选取代的融合芳香环；RL是一个C5-7芳基基团，在meta位被R2基团取代，且可选取进一步取代；其中R2被选自：2，并且它被用作一种药物，特别是用于治疗通过抑制PARP活性改善的疾病。
• 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES
  申请人：Kudos Pharmaceuticals Ltd

  公开号：EP1948642A1

  公开（公告）日：2008-07-30
• US7196085B2
  申请人：——

  公开号：US7196085B2

  公开（公告）日：2007-03-27